Sunday 18 October 2026
Export NERV’s income statement to Excel — free account
Minerva Neurosciences, Inc
NERV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 183.7% and free cash flow fell 553.5%, each against the same quarter a year earlier.
2.35
0.07
−2.89%
Follow NERV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 322.05% | 293.17% | 352.58% | 49.88% |
+8 more TTM periods Free account |
|
| (629.71%) | (654.56%) | (434.34%) | (39.57%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(521.51%) | (556.22%) | (363.11%) | (135.54%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.56) | (0.34) | (1.60) | (1.88) | |
Free Cash Flow |
(26.17) | (14.87) | (13.51) | (14.20) | |
| Other line items | |||||
Cash ROIC |
18.97% | 8.45% | 23.16% | 63.97% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.07 | 0.04 | 0.05 | 1.01 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 3.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (0.34) | (1.60) | (1.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates